West Haven, CTNCT04587791Now EnrollingIRB Ready

Chronic Pain Clinical Trial in West Haven, CT

Access cutting-edge chronic pain treatment through this clinical trial at a research site in West Haven. Study-provided care at no cost to qualified participants.

Sponsored by Yale University

Quick Self-Assessment

See if you qualify for this West Haven location

Preparing your pre-screening questions…

Expert Care in West Haven

Access chronic pain specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic pain treatment provided free

Apply for This West Haven Location

Check if you qualify for this chronic pain clinical trial in West Haven, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to West Haven

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit West Haven site if eligible
  4. 4Begin participation

About This Chronic Pain Study in West Haven

This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of Cannabidiol (CBD) on measures of pain and opioid craving in outpatients with opioid use disorder (OUD) receiving medication-assisted treatment with methadone or buprenorphine. With a duration of approximately 4 weeks, participants will come to the testing site for a total of five times: one initial screening session, and four experimental sessions where study medication, CBD, will be administered, separated by at least 72 hours to limit carryover effects.

Sponsor: Yale University

Who Can Participate

Inclusion Criteria

Males and females, Veterans and non-Veterans, aged between 18 and 70 years old.
Diagnosed with OUD and currently enrolled in methadone or buprenorphine maintenance treatment.
Having chronic pain, uniformly operationalized as grade II (high-intensity) non-cancer pain for ≥ 6 months.
Capable of providing informed consent in English.
Compliant in opioid maintenance treatment and on a stable dose for four weeks or longer.
Not meeting DSM-5 criteria for substance use disorders other than OUD or tobacco use disorder within the last 12 months.
No current medical problems deemed contraindicated for participation by principal investigator.
For women, not pregnant as determined by pregnancy screening; not breast-feeding; using acceptable birth control methods. Acceptable contraception for females includes oral contraceptives, contraceptive depot injections, contraceptive subdermal implants, intrauterine devices, or surgical contraception methods. Acceptable contraception for males includes condoms or surgical contraception methods.

Exclusion Criteria

Other current major psychiatric disorders deemed clinically unstable by the principal investigator, such as severe depression and/or active suicidal ideation.
Having experienced major psychosocial stressors recently (≤ 6 weeks before enrollment), at the discretion of the principal investigator.
Methadone dose under 30 mg or over 150 mg/day.
Buprenorphine dose over 24 mg per day.
Having received inpatient psychiatric treatment recently (≤ 60 days before enrollment).
Candidates receiving products containing either THC or CBD will be excluded. All participants will be asked to abstain from cannabinoids. Prior to receiving the study medication on the first test session, participants' cannabinoid use will be assessed using a quantitative point-of-care urine 11-nor-9-carboxy-THC concentration test with a cut-off of ≤ 50 mg/mL. If a participant tests greater than ≤50 mg/mL, they will be asked to abstain for an additional 7 to 14 days. If 14 days after their initial THC concentration test the participant continues to test positive, they will not be allowed to participate in the study.
A physician will carefully evaluate participants for use of over-the-counter or prescription psychoactive drugs known to affect pain threshold or pain tolerance (including NSAIDS, serotonin-norepinephrine reuptake inhibitors (SNRIs) (e.g. venlafaxine, duloxetine), gabapentinoids, tricyclic antidepressants (e.g., nortriptyline, amitriptyline), anticonvulsant medications (e.g., topiramate, carbamazepine)). Only participants who are on stable doses (i.e., consistent daily administration of the medication for at least three months at the same dose following the last dose change, either increase or decrease) of these medications, and whose dosing schedules allow participation in the study visits, thus excluding instances of single-dose or temporary dosing of the medication, will be eligible as determined by principal investigator. If possible, the morning dose will be administered after the study visit.
Current, regular use of benzodiazepines, other prescription opioids, or platelet inhibitors (e.g., clopidogrel, apixaban, ticagrelor).
Current weight of less of 60 kg.
Allergy to sesame seed oil, which is an ingredient of the CBD formulation used.
Serious medical or neurological illness or treatment for a medical disorder that could interfere with study participation as determined by principal investigator.
Participants who have elevation of liver enzymes (ALT and/or AST) 2x above the normal limit or higher.
Contraindications for exposure to cold temperatures, such as Raynaud's phenomenon and hypertension.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in West Haven?

Yes, this clinical trial (NCT04587791) has an active research site in West Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Pain Treatment Options in West Haven, CT

If you're searching for chronic pain treatment options in West Haven, CT, this clinical trial (NCT04587791) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our West Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic pain specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic pain clinical trials near you to find additional studies recruiting in your area.

More Chronic Pain Trials in West Haven, CT

See all chronic pain clinical trials recruiting in West Haven — not just this study.

Browse Chronic Pain Trials in West Haven →

Browse More Trials by Condition

Chronic Pain TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in West Haven?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · West Haven, CT